Daiichi Sankyo's Factor Xa Bests Enoxaparin In Phase III Trial For VTE
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo announced July 12 its factor Xa inhibitor edoxaban posted superior results to Sanofi-Aventis' Lovenox (enoxaparin), a low dose heparin, in preventing venous thromboembolic events in patients following total knee replacement. The announcement will put Daiichi Sankyo's marketing chops to the test, as the compound, while clear in its efficacy, is primed to enter a market with a number of potential factor Xa competitors in a Japanese antithrombotic market still dominated by heparin and warfarin
You may also be interested in...
Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
TOKYO - Daiichi Sankyo's R&D leaders are optimistic about how factor Xa inhibitor edoxaban can compete in a potentially crowded market, but the company is also shifting its focus to development of first-in-class compounds, citing commercial and regulatory hurdles for follow-on, best-in-class products
Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
TOKYO - Daiichi Sankyo's R&D leaders are optimistic about how factor Xa inhibitor edoxaban can compete in a potentially crowded market, but the company is also shifting its focus to development of first-in-class compounds, citing commercial and regulatory hurdles for follow-on, best-in-class products
Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
Because regulators and the market have become less accepting of follow-on compounds, the Japanese pharma plans to invest in first-in-class science, pursuing best-in-class opportunities only when it sees a substantial unmet medical need.